AI Novel Coronavirus and Epidemic Market
1 Introduction to Research & Analysis Reports
1.1 AI to Novel Coronavirus (COVID-19) and Epidemic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global AI to Novel Coronavirus (COVID-19) and Epidemic Overall Market Size
2.1 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size: 2021 VS 2028
2.2 Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top AI to Novel Coronavirus (COVID-19) and Epidemic Players in Global Market
3.2 Top Global AI to Novel Coronavirus (COVID-19) and Epidemic Companies Ranked by Revenue
3.3 Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Companies
3.4 Top 3 and Top 5 AI to Novel Coronavirus (COVID-19) and Epidemic Companies in Global Market, by Revenue in 2021
3.5 Global Companies AI to Novel Coronavirus (COVID-19) and Epidemic Product Type
3.6 Tier 1, Tier 2 and Tier 3 AI to Novel Coronavirus (COVID-19) and Epidemic Players in Global Market
3.6.1 List of Global Tier 1 AI to Novel Coronavirus (COVID-19) and Epidemic Companies
3.6.2 List of Global Tier 2 and Tier 3 AI to Novel Coronavirus (COVID-19) and Epidemic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size Markets, 2021 & 2028
4.1.2 AI Tracking
4.1.3 AI Predict
4.1.4 AI Recognition
4.1.5 Other
4.2 By Type - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue & Forecasts
4.2.1 By Type - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2017-2022
4.2.2 By Type - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2023-2028
4.2.3 By Type - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2021 & 2028
5.1.2 Medical
5.1.3 Public Emergency
5.1.4 Other
5.2 By Application - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue & Forecasts
5.2.1 By Application - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2017-2022
5.2.2 By Application - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2023-2028
5.2.3 By Application - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2021 & 2028
6.2 By Region - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue & Forecasts
6.2.1 By Region - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2017-2022
6.2.2 By Region - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2023-2028
6.2.3 By Region - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2017-2028
6.3.2 US AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.3.3 Canada AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.3.4 Mexico AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2017-2028
6.4.2 Germany AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.4.3 France AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.4.4 U.K. AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.4.5 Italy AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.4.6 Russia AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.4.7 Nordic Countries AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.4.8 Benelux AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2017-2028
6.5.2 China AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.5.3 Japan AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.5.4 South Korea AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.5.5 Southeast Asia AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.5.6 India AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2017-2028
6.6.2 Brazil AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.6.3 Argentina AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2017-2028
6.7.2 Turkey AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.7.3 Israel AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.7.4 Saudi Arabia AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
6.7.5 UAE AI to Novel Coronavirus (COVID-19) and Epidemic Market Size, 2017-2028
7 Players Profiles
7.1 Google
7.1.1 Google Corporate Summary
7.1.2 Google Business Overview
7.1.3 Google AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.1.4 Google AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.1.5 Google Key News
7.2 Alibaba
7.2.1 Alibaba Corporate Summary
7.2.2 Alibaba Business Overview
7.2.3 Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.2.4 Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.2.5 Alibaba Key News
7.3 Artificial Intelligence in Medical Epidemiology
7.3.1 Artificial Intelligence in Medical Epidemiology Corporate Summary
7.3.2 Artificial Intelligence in Medical Epidemiology Business Overview
7.3.3 Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.3.4 Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.3.5 Artificial Intelligence in Medical Epidemiology Key News
7.4 BlueDot
7.4.1 BlueDot Corporate Summary
7.4.2 BlueDot Business Overview
7.4.3 BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.4.4 BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.4.5 BlueDot Key News
7.5 Beijing Infervision Technology Co., Ltd.
7.5.1 Beijing Infervision Technology Co., Ltd. Corporate Summary
7.5.2 Beijing Infervision Technology Co., Ltd. Business Overview
7.5.3 Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.5.4 Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.5.5 Beijing Infervision Technology Co., Ltd. Key News
7.6 BenevolentAI
7.6.1 BenevolentAI Corporate Summary
7.6.2 BenevolentAI Business Overview
7.6.3 BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.6.4 BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.6.5 BenevolentAI Key News
7.7 SenseTime
7.7.1 SenseTime Corporate Summary
7.7.2 SenseTime Business Overview
7.7.3 SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.7.4 SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.7.5 SenseTime Key News
7.8 Insilico Medicine
7.8.1 Insilico Medicine Corporate Summary
7.8.2 Insilico Medicine Business Overview
7.8.3 Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.8.4 Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.8.5 Insilico Medicine Key News
7.9 DEARGEN
7.9.1 DEARGEN Corporate Summary
7.9.2 DEARGEN Business Overview
7.9.3 DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.9.4 DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.9.5 DEARGEN Key News
7.10 Iktos
7.10.1 Iktos Corporate Summary
7.10.2 Iktos Business Overview
7.10.3 Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.10.4 Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.10.5 Iktos Key News
7.11 SRI Biosciences
7.11.1 SRI Biosciences Corporate Summary
7.11.2 SRI Biosciences Business Overview
7.11.3 SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Major Product Offerings
7.11.4 SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global Market (2017-2022)
7.11.5 SRI Biosciences Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. AI to Novel Coronavirus (COVID-19) and Epidemic Market Opportunities & Trends in Global Market
Table 2. AI to Novel Coronavirus (COVID-19) and Epidemic Market Drivers in Global Market
Table 3. AI to Novel Coronavirus (COVID-19) and Epidemic Market Restraints in Global Market
Table 4. Key Players of AI to Novel Coronavirus (COVID-19) and Epidemic in Global Market
Table 5. Top AI to Novel Coronavirus (COVID-19) and Epidemic Players in Global Market, Ranking by Revenue (2021)
Table 6. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Share by Companies, 2017-2022
Table 8. Global Companies AI to Novel Coronavirus (COVID-19) and Epidemic Product Type
Table 9. List of Global Tier 1 AI to Novel Coronavirus (COVID-19) and Epidemic Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 AI to Novel Coronavirus (COVID-19) and Epidemic Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2023-2028
Table 30. Google Corporate Summary
Table 31. Google AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 32. Google AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 33. Alibaba Corporate Summary
Table 34. Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 35. Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 36. Artificial Intelligence in Medical Epidemiology Corporate Summary
Table 37. Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 38. Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 39. BlueDot Corporate Summary
Table 40. BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 41. BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 42. Beijing Infervision Technology Co., Ltd. Corporate Summary
Table 43. Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 44. Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 45. BenevolentAI Corporate Summary
Table 46. BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 47. BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 48. SenseTime Corporate Summary
Table 49. SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 50. SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 51. Insilico Medicine Corporate Summary
Table 52. Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 53. Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 54. DEARGEN Corporate Summary
Table 55. DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 56. DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 57. Iktos Corporate Summary
Table 58. Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 59. Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
Table 60. SRI Biosciences Corporate Summary
Table 61. SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Product Offerings
Table 62. SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. AI to Novel Coronavirus (COVID-19) and Epidemic Segment by Type in 2021
Figure 2. AI to Novel Coronavirus (COVID-19) and Epidemic Segment by Application in 2021
Figure 3. Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global AI to Novel Coronavirus (COVID-19) and Epidemic Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by AI to Novel Coronavirus (COVID-19) and Epidemic Revenue in 2021
Figure 8. By Type - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
Figure 9. By Application - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
Figure 10. By Region - Global AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
Figure 11. By Country - North America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
Figure 12. US AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 13. Canada AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
Figure 16. Germany AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 17. France AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 19. Italy AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 20. Russia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
Figure 24. China AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 25. Japan AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 28. India AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
Figure 30. Brazil AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Market Share, 2017-2028
Figure 33. Turkey AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 34. Israel AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 36. UAE AI to Novel Coronavirus (COVID-19) and Epidemic Revenue, (US$, Mn), 2017-2028
Figure 37. Google AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Alibaba AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Artificial Intelligence in Medical Epidemiology AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. BlueDot AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Beijing Infervision Technology Co., Ltd. AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. BenevolentAI AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. SenseTime AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Insilico Medicine AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. DEARGEN AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Iktos AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. SRI Biosciences AI to Novel Coronavirus (COVID-19) and Epidemic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
